Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

93
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
93
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

555
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
555
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

293
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
293
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

103
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
103
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

221
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
221
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

343
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
343
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. マルチサイト米国コホートにおける高感度心臓トロポニンt戦略と臨床変数の診断性能

マルチサイト米国コホートにおける高感度心臓トロポニンT戦略と臨床変数の診断性能

Brandon R Allen1, Robert H Christenson2, Scott A Cohen1

  • 1Department of Emergency Medicine, College of Medicine (B.R.A., S.A.C., C.M.), University of Florida, Gainesville.

Circulation
|January 21, 2021

関連する実験動画

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

7.6K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.9K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.5K

PubMed で要約を見る

まとめ
この要約は機械生成です。

低リスクのHEARTスコアと,定量化限界を下回る初期高感度トロポニンT (hs- cTnT) を組み合わせると,30日間の主要な不良心事 (MACE) の99%の負の予測値が示されます. この戦略は,急性冠動脈症候群の可能性のある緊急治療室の患者に有効です.

科学分野:

  • 心臓病科
  • 緊急 医療
  • 診断 の 正確 さ

背景:

  • 低高感度トロポニン (hs-cTn) または0/1時間のアルゴリズムを使用して,緊急治療室で心筋梗塞を排除するための欧州データサポート.
  • 急性冠動脈症候群のこれらの診断戦略を検証する米国でのデータは限られている.
  • この研究は,米国のコホートにおけるhs- cTnTのパフォーマンスを評価することを目的とした.

研究 の 目的:

  • 定量化限界 (LOQ) 以下の初期hs-cTnTの診断性能を評価する.
  • 主要な不良心事 (MACE) を排除するための0/1時間のhs-cTnTアルゴリズムを評価する.
  • hs- cTnT戦略とMACE排除のためのHEARTスコアを組み合わせた有用性を決定する.

主な方法:

  • 急性冠動脈症候群の成人患者を対象とした米国8カ所の前向きなコホート研究.
  • ベースラインと1時間のhs- cTnTレベルを測定し,医師は結果に盲目的にHEARTスコアを計算した.
  • 判断された30日間のMACE (心臓死,心筋梗塞,再血管化) と計算された負の予測値 (NPV)

主要な成果:

  • 1462人の参加者の32. 8%がLOQ以下の初期hs- cTnTで,30日間のMACEでは98. 3%のNPVが得られました.
キーワード:
急性冠動脈症候群胸の痛み心筋梗塞トロポニン

関連する実験動画

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

7.6K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.9K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.5K
  • LOQより低い初期hs- cTnTの低リスクHEARTスコアは,30日間のMACEで99. 0%のNPVを達成しました.
  • 0/ 1時間のアルゴリズムは97. 2%のNPVを持つ患者の57. 8%を排除し,低いHEARTスコアを加えるとNPVは98. 4%に改善しました.

    • 結論:

    • LOQ以下の初期hs- cTnTと低リスクのHEARTスコアは,米国のコホートで30日間のMACEで99%のNPVを示した.
    • 0/1時間 hs-cTnT アルゴリズムは単独またはHEARTスコアで一貫して>99%のNPVを達成しませんでした.
    • 緊急治療室の患者にMACEを安全に排除するための統合戦略を裏付けています.